v3.25.4
Significant agreements - Neurocrine Collaboration Agreements (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 01, 2023
Jan. 08, 2023
USD ($)
$ / shares
shares
Nov. 30, 2025
USD ($)
Oct. 31, 2025
USD ($)
Apr. 30, 2025
item
Sep. 30, 2024
USD ($)
Feb. 29, 2024
USD ($)
Feb. 28, 2023
USD ($)
item
Program
$ / shares
shares
Oct. 31, 2021
USD ($)
Mar. 31, 2019
USD ($)
item
$ / shares
shares
Sep. 30, 2024
USD ($)
Dec. 31, 2025
USD ($)
item
shares
Dec. 31, 2024
USD ($)
item
Dec. 31, 2023
USD ($)
item
Jun. 30, 2024
USD ($)
Apr. 30, 2024
USD ($)
Dec. 31, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaboration revenue (including from related parties, see note 12)                       $ 40,374 $ 80,001 $ 250,008      
Contract with Customer, Liability, Noncurrent                         6,003        
Contract with Customer, Asset, Net, Current                       151 676        
Contract with Customer, Liability, Current                       1,590 24,394        
Option and License Agreement | Alexion                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Contract with customer liability revenue recognized                       $ 0 0 0      
Allocation of transaction price                                 $ 15,000
Upfront payment                 $ 30,000                
Aggregate milestone payments, if exercise rights                 10,000                
Option and License Agreement | Alexion | Development, regulatory and commercialization milestone                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Aggregate maximum milestone payments to be received from collaborative partner                 115,000                
Option and License Agreement | Alexion | Sales milestone                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Aggregate maximum milestone payments to be received from collaborative partner                 $ 175,000                
2019 Neurocrine Collaborative Agreement                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Number of discovery programs | item         2                        
Number of undisclosed programs | item                   2              
2019 Neurocrine Collaborative Agreement | FA Program                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Percentage of profit or loss under co-co option                   40.00%              
2019 Neurocrine Collaborative Agreement | Neurocrine                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Milestone payments             $ 5,000                    
Deferred revenue                         2,800        
Allocation of transaction price             5,000                    
Issuance of common stock, shares | shares                   4,179,728   4,179,728          
Upfront payment                   $ 115,000   $ 115,000          
Price per share | $ / shares                   $ 11.9625              
Purchase of common stock                   $ 50,000   5,000          
Estimated cost reimbursement                       431,100          
Reimbursements expected                       82,100          
Termination period                   10 years              
Discount related to equity investment                       27,600          
Equity investment                       50,000          
Cumulative catch up of revenue recognized             4,400                    
Milestone payment to be received             $ 5,000                    
Reimbursement costs expected to be received                       100 400        
Contract with Customer, Liability, Current                       300          
Allocation of Transaction Price                                  
Allocation of fixed consideration                       97,400          
2019 Neurocrine Collaborative Agreement | Neurocrine | Maximum                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Percentage of reduction in royalty payments                   50.00%              
2019 Neurocrine Collaborative Agreement | Neurocrine | FA Program                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Percentage of profit or loss under co-co option                   60.00%              
2019 Neurocrine Collaborative Agreement | Neurocrine | Active programs                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Contract with customer liability revenue recognized                       $ 3,500 10,400 9,800      
2019 Neurocrine Collaborative Agreement | Neurocrine | Development and regulatory milestones | FA Program                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Aggregate maximum milestone payments to be received from collaborative partner                   $ 195,000              
2019 Neurocrine Collaborative Agreement | Neurocrine | Commercial milestone                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Per milestone, maximum milestone payments to be received from collaborative partner                   275,000              
Aggregate maximum milestone payments to be received from collaborative partner                   $ 550,000              
2023 Neurocrine Collaborative Agreement                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Percentage of profit or loss under co-co option 50.00%                                
Percentage of development costs incurred 50.00%                                
Purchase of common stock                           31,121      
2023 Neurocrine Collaborative Agreement | Development milestone | Minimum                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Number of countries received regulatory approval | item                       1          
2023 Neurocrine Collaborative Agreement | Neurocrine                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Milestone payments     $ 3,000 $ 3,000   $ 3,000   $ 3,000                  
Contract with customer liability revenue recognized     $ 2,800                            
Deferred revenue                       $ 200          
Allocation of transaction price           $ 3,000         $ 3,000            
Number of discovery programs | item                       3          
Number of development and commercialization licenses | item                       2          
Contract with Customer, Liability, Noncurrent                         5,300        
Contract with Customer, Asset, Net, Current                       $ 100 300        
Issuance of common stock, shares | shares   4,395,588           4,395,588                  
Amount of premium               $ 7,900                  
Percentage of profit or loss under co-co option 50.00%                                
Upfront payment               $ 136,000                  
Price per share | $ / shares   $ 8.88           $ 8.88                  
Purchase of common stock   $ 39,000           $ 39,000                  
Termination period               10 years                  
Discount related to equity investment               $ 39,000                  
Cumulative catch up of revenue recognized                     $ 2,000 1,300 27,600        
Milestone payment to be received                             $ 3,000 $ 3,000  
Reimbursement costs expected to be received                       9,800          
Costs to obtain collaboration agreement                           400      
Contract with Customer, Liability, Current                         22,300        
Allocation of Transaction Price                                  
Allocation of fixed consideration               $ 143,900                  
2023 Neurocrine Collaborative Agreement | Neurocrine | GBA1                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Contract with customer liability revenue recognized                         3,000 69,500      
2023 Neurocrine Collaborative Agreement | Neurocrine | GBA1 | Maximum                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Number of products | item               2                  
2023 Neurocrine Collaborative Agreement | Neurocrine | Discovery Programs 2023                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Contract with customer liability revenue recognized                       $ 26,500 $ 44,500 $ 5,500      
Number of discovery programs | item                       3 3 3      
2023 Neurocrine Collaborative Agreement | Neurocrine | Development milestone                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Discovery programs under development | Program               3                  
2023 Neurocrine Collaborative Agreement | Neurocrine | Development milestone | GBA1                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Contract with customer liability revenue recognized                       $ 2,800          
Aggregate maximum milestone payments to be received from collaborative partner               $ 985,000                  
2023 Neurocrine Collaborative Agreement | Neurocrine | Development milestone | Discovery Programs 2023                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Aggregate maximum milestone payments to be received from collaborative partner               175,000                  
2023 Neurocrine Collaborative Agreement | Neurocrine | Commercial milestone | GBA1 | Maximum                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Per milestone, maximum milestone payments to be received from collaborative partner               950,000                  
2023 Neurocrine Collaborative Agreement | Neurocrine | Commercial milestone | Discovery Programs 2023                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Per milestone, maximum milestone payments to be received from collaborative partner               $ 275,000                  
Number of products | item               1                  
2023 Neurocrine Collaborative Agreement | Neurocrine | Research and development milestone                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Contract with customer liability revenue recognized                       1,200 $ 2,200        
2023 Neurocrine Collaborative Agreement | Neurocrine | Research and development milestone | GBA1                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Contract with customer liability revenue recognized                           $ 5,800      
2023 Neurocrine Collaborative Agreement and 2019 Neurocrine Collaborative Agreement                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Deferred revenue                       1,590 30,397        
Contract with Customer, Asset, Net, Current                       151 $ 676        
2023 Neurocrine Collaborative Agreement and 2019 Neurocrine Collaborative Agreement | Neurocrine | Discovery program 3                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaboration revenue recognized                       $ 31,800